88368-11-0

Upstream product

• 1073-70-7 4-chlorophenylhydrazine hydrochloride 
• 504-02-9 1,3-cylohexanedione 
• 473403-22-4 cyclohexane-1,3-dione mono-(4-chlorophenyl)hydrazone 
• 63069-48-7 p-chloro-o-iodoaniline 
• 1057113-82-2 cyclohexane-1,3-dione-mono-(4-chlorophenyl)hydrazone 
• 36646-75-0 3-(4-choloroaniline)-2-cyclohexen-1-one 
• 108-94-1 cyclohexanone 
• 36684-65-8 6-chloro-1,2,3,4-tetrahydrocarbazole 
• 106-47-8 4-chloro-aniline 

Downstream Products

• 329728-69-0 9-benzyl-6-chloro-1,2,3,9-tetrahydro-4H-carbazol-4-one 
• 329728-74-7 6-chloro-9-(4-fluorobenzyl)-1,2,3,9-tetrahydrocarbazol-4-one 
• 1057113-83-3 6-chloro-1-(phenylsulfonyl)-4-oxo-1,2,3,4-tetrahydrocarbazole 

Relevant academic research and scientific papers

Hypervalent Iodine(III)-Mediated Counteranion Controlled Intramolecular Annulation of Exocyclic β-Enaminone to Carbazolone and Imidazo[1,2-a]pyridine Synthesis

A highly efficient and flexible protocol for intramolecular annulation of exocyclic β-enaminones has been disclosed for the synthesis of carbazolones and imidazo[1,2-a]pyridines through a counter-anion-controlled free-radical mechanism promoted by hypervalent iodine(III). The cooperative behavior of HTIB and AgSbF6 plays a crucial role in the intramolecular annulation process through C?C and C?N bond formation to give the desired products. The mechanistic insights suggest that the two competitive reactions involved in the system are guided by the nature of the counteranion, which determines the formation of the final products. A wide variety of carbazolones and imidazo[1,2-a]pyridine molecules have been prepared and isolated in good to excellent yields.

A catalyst free synthesis of 8, 9, 11-trihalo-5H-benzofuro[3,2-c]carbazol-10-ols

8, 9, 11-Trichloro-5H-benzofuro[3,2-c]carbazol-10-ol analogues have been synthesized by treating 2,3-dihydro-1H-carbazol-4(9H)-one with chloranil/fluoranil without any catalyst and is found to be applicable across a range of carbazolone substrates. A possible mechanism has been proposed.

Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use

This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. The compounds may bind to and antagonize receptor α2B, α1B or α2A. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption, or to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. The compounds may also be used to treat diseases or conditions that are expected to be responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular, renal disorders or type 2 diabetes is particularly described.

Inhibiting NF-κB-inducing kinase (NIK): Discovery, structure-based design, synthesis, structure-activity relationship, and co-crystal structures

The discovery, structure-based design, synthesis, and optimization of NIK inhibitors are described. Our work began with an HTS hit, imidazopyridinyl pyrimidinamine 1. We utilized homology modeling and conformational analysis to optimize the indole scaffol

COMPOUNDS AND METHODS OF TREATING HYPERTENSION

Hydrogenated pyrido[4,3-b]indoles, pyrido [3, 4-b] indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor α2B antagonists. The compounds may also bind to and antagonize adrenergic receptor α2

FUSED TETRACYCLIC PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]ONDOLE DERIVATIVES AND METHODS OF USE

This disclosure is directed to fused tetracyclic pyrido[4,3-b]indoles and pyrido[3,4- b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

FUSED TETRACYCLIC PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]INDOLE DERIVATIVES AND METHODS OF USE

This disclosure is directed to fused tetracyclic pyrido[4,3-b>]indole and pyrido [3, 4-b] indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applica

PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]INDOLE DERIVATIVES AND METHODS OF USE

This disclosure is directed to pyrido[4,3-b]indole and pyrido [3,4-b] indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]INDOLE DERIVATIVES AND METHODS OF USE

This disclosure is directed to pyrido[4,3-b]indole and pyrido[3, 4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the

PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE

This disclosure is directed to tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder